Artemisinin resistance

Show results for

Unknown (913)
Genomics (88)
Transcriptomics (36)
Proteomics (20)
Metabolomics (10)
Models (1)
Other (1)

Organisms

Plasmodium falciparum (40)
Andropogon gerardi (17)
Bacteria (17)
Canis lupus familiaris (17)
Clostridium perfringens (17)
Cnidaria (17)
Cricetulus griseus (17)
Eukaryota (17)
Fasciola (17)
Hepatitis B virus (17)
Human betaherpesvirus 5 (17)
Japanese encephalitis virus group (17)
Madurella mycetomatis (17)
Mesocricetus auratus (17)
Miscanthus x giganteus (17)
Mycobacterium tuberculosis (17)
Orthoflavivirus (17)
Panicum virgatum (17)
Platyhelminthes (17)
Pseudomonas aeruginosa AES-1R (17)
Rickettsia (17)
Saccharomyces cerevisiae (17)
Schizosaccharomyces pombe (17)
Severe acute respiratory syndrome coronavirus 2 (17)
Shigella (17)
Plasmodium knowlesi (1)
Saccharomyces cerevisiae (1)
Homo sapiens (1)
Plasmodium berghei (1)
Vibrio cholerae (1)

Organisms

Plasmodium falciparum (32)
Plasmodium falciparum 3D7 (2)
Vibrio cholerae (1)
Plasmodium berghei (1)
Homo sapiens (1)

Repository

ENA (82)
geo (27)
pride (17)
biostudies-arrayexpress (16)
MetaboLights (9)
jPOST (2)
BioModels (1)
MassIVE (1)
MetabolomicsWorkbench (1)

Tissue

Blood (8)
Blood cell (6)
Erythrocyte (2)
Parasite (1)
Blood plasma (1)
Flower bud (1)
Leaf (1)
Permanent cell line cell (1)
Plant cell (1)

Disease

Plasmodium falciparum malaria (7)
Malaria (3)
Malaria (1)

Technology Type

Mass Spectrometry (18)
Shotgun proteomics (10)
Mass spectrometry assay (5)
SWATH MS (5)
Mass spectrometry (4)
Bottom-up proteomics (3)
Affinity purification coupled with mass spectrometry proteomics (2)
Data-dependent acquisition (2)
ESI (1)
SRM/MRM (1)

Instrument Platform

Liquid Chromatography MS - negative - reverse-phase (3)
Liquid Chromatography MS - positive - reverse-phase (3)
Liquid Chromatography MS - negative - hilic (3)
Liquid Chromatography MS - negative - reverse phase (2)
Liquid Chromatography MS - positive - reverse phase (2)
Liquid Chromatography MS - positive - hilic (2)
Q Exactive (1)
Liquid Chromatography MS - positive - hydrophilic-interaction-liquid-chromatography (1)
Liquid Chromatography MS - negative - hydrophilic-interaction-liquid-chromatography (1)
Liquid Chromatography MS - positive (1)

Publication Date

2022 (11)
2025 (8)
2010 (6)
2026 (6)
2024 (5)
2015 (5)
2014 (5)
2013 (5)
2021 (5)
2016 (3)
2020 (3)
2012 (2)
2023 (2)
2019 (2)
2018 (2)
2011 (1)
2008 (1)

CHEBI ID

CHEBI:15354 (2)
CHEBI:73510 (2)
CHEBI:73635 (2)
CHEBI:74750 (2)
CHEBI:73704 (2)
CHEBI:16708 (2)
CHEBI:162647 (1)
CHEBI:161369 (1)
CHEBI:161869 (1)
CHEBI:163638 (1)
CHEBI:164245 (1)
CHEBI:163433 (1)
CHEBI:162782 (1)
CHEBI:162580 (1)
CHEBI:163199 (1)
CHEBI:183193 (1)
CHEBI:164306 (1)
CHEBI:159357 (1)
CHEBI:164405 (1)
CHEBI:160416 (1)
CHEBI:159031 (1)
CHEBI:163823 (1)
CHEBI:166121 (1)
CHEBI:162893 (1)
CHEBI:159955 (1)
CHEBI:159205 (1)
CHEBI:164209 (1)
CHEBI:162680 (1)
CHEBI:158497 (1)
CHEBI:160858 (1)

Metabolite Name

Artemisinin (7)
Hypoxanthine (6)
Choline (6)
L-Histidine (5)
Adenine (5)
Glycylprolylhydroxyproline (4)
Cafestol (4)
Aspartame (4)
L-Threonine (4)
Guanosine (4)
Uridine (4)
Riboflavin (4)
Melibiose (4)
L-Tyrosine (4)
Glu-Thr (4)
L-Glutamate (4)
Oleamide (4)
Stearamide (4)
Pyridoxine (4)
Bufalin (4)
L-Arginine (4)
Betaine (4)
Acetylcarnitine (4)
Dethiobiotin (4)
Creatine (4)
Adenosine (4)
Marrubiin (3)
Cyclopiazonic acid (3)
Ala-Pro (3)
Ingenol (3)

IsPrivate

False (1)

Submitter Keywords

FROG (1)

First Public Date

2025 (17)
2024 (12)
2014 (9)
2026 (7)
2018 (7)
2022 (6)
2021 (6)
2020 (6)
2023 (4)
2015 (3)
2019 (2)
2017 (2)
2013 (1)

Classification

protozoa (35)
bacteria (1)

Modelling Approach

Constraint-based model (1)

Study type

Transcription profiling by array (10)
Comparative genomic hybridization by array (5)
ChIP-chip by array (1)

Release Date

2024 (89)
2021 (88)
2020 (88)
2022 (85)
2018 (78)
2023 (75)
2025 (73)
2015 (63)
2017 (59)
2016 (56)
2019 (55)
2014 (29)
2013 (23)
2012 (14)
2011 (14)
2010 (11)
2026 (9)
2008 (6)
2009 (5)
2006 (3)
2007 (2)
2000 (2)
2005 (1)
2002 (1)

Lab affiliation

Department of Immunology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning 110122, China (3)
Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia (2)
Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy ofChinese Medical Sciences (1)
Chemistry, Duke University, USA (1)
Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, USA (1)
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia (1)
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (1)
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France (1)
Joint International Research Laboratory of Metabolic & Developmental Sciences, Key Laboratory of Urban Agriculture (South) Ministry of Agriculture, Plant Biotechnology Research Center, Fudan-SJTU-Nottingham Plant Biotechnology R&D Center, School of Agriculture and Biology, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, P. R. China (1)
Malaria Biology Group, ICGEB, New Delhi, India (1)
Parasitology Section Bernhard Nocht Institute for Tropical Medicine Bernhard-Nocht-Str. 74 20359 Hamburg Germany (1)
Proteomics Care Facilty, Biozentrum, University of Basel, Switzerland (1)
Proteomics platform 3P5-Necker, Université Paris Descartes - Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Paris 75014, France. (1)
School of Biological Sciences (1)

Previous page
1 / 107
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 107
Next page

Sort by:

Relevance

Page size

K13 mutations driving artemisinin resistance rewrite Plasmodium falciparum’s programmed intra-erythrocytic development and transform mitochondrial physiology

Not available

ORGANISM(S): Plasmodium falciparum

ST001279 | MetabolomicsWorkbench

Structural polymorphism in the promoter of pfmrp2 confers tolerance to mefloquine and chloroquine in Plasmodium falciparum [CGH]

Drug resistance in Plasmodium falciparum remains a challenge for the malaria eradication programs around the world. With the emergence of artemisinin resistance, the efficacy of the partner drugs in the artemisinin combination therapies (ACT) that include quinoline based drugs is becoming critical. ...

ORGANISM(S): Plasmodium falciparum

2013-02-07 | E-GEOD-44128 | biostudies-arrayexpress

Structural polymorphism in the promoter of pfmrp2 confers tolerance to mefloquine and chloroquine in Plasmodium falciparum [expression]

ORGANISM(S): Plasmodium falciparum

2013-02-07 | E-GEOD-44127 | biostudies-arrayexpress

Structural polymorphism in the promoter of pfmrp2 confers tolerance to mefloquine and chloroquine in Plasmodium falciparum.

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

ORGANISM(S): Plasmodium falciparum

2013-02-07 | E-GEOD-44129 | biostudies-arrayexpress

Metabolisme of artemisinin-resistant falciparum malaria parasites: are apicoplast and mitochondrion pathways key targets?

In the context of artemisinin resistance, the objective of the project was to evaluate the role of apicoplast and mitochondrion pathways during the parasite quiescent state induced by dihydroartemisinin (DHA) treatment. We analysed the proteome of artemisinin-resistant parasites in two conditions: a...

ORGANISM(S): Plasmodium falciparum

2025-05-06 | PXD048354 | Pride

Analysis of anti-malarial resistance markers in pfmdr1 and pfcrt across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration.

Not available

S-EPMC5101715 | biostudies-literature

Mechanisms of PfDNMT2 inhibition and PfATP6-mediated resistance to the antimalarial candidate SC83288 in Plasmodium falciparum

The emergence of multi-drug resistant Plasmodium falciparum underscores the urgent need for new antimalarial therapies. SC83288, a novel chemical entity, is highly effective against P. falciparum both in vivo and in vitro, including strains resistant to artemisinin and partner drugs. Here, we sho...

2026-02-16 | MTBLS13911 | MetaboLights

Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription

This SuperSeries is composed of the following subset Series: GSE25878: Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription (expression) GSE25879: Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern...

ORGANISM(S): Plasmodium falciparum

2010-12-07 | E-GEOD-25883 | biostudies-arrayexpress

tRNA modification reprogramming of Plasmodium falciparum as a feature of artemisinin resistance

Artemisinin (ART)-resistant Plasmodium falciparum (Pf) threatens global malaria control. Resistance, driven by mutations in Pfk13, is multifaceted but quiescence plays a central role. Epigenetic regulation may contribute, given that only a percentage of parasites survive a pulse of the active drug m...

ORGANISM(S): Plasmodium falciparum

2024-06-22 | PXD043747 | Pride

Plasmodium Artemisinin Rna modification

Polymorphisms in the K13-Propeller Gene in Artemisinin-Resistant Plasmodium in Mice.

Not available

S-EPMC9653030 | biostudies-literature

Previous page
1 / 107
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 107
Next page

Sort by:

Relevance

Page size

1069 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

IsPrivate

Submitter Keywords

First Public Date

Classification

Modelling Approach

Study type

Release Date

Lab affiliation

Tags

OmicsDI is part of the ELIXIR infrastructure

Tweets